Aloe polymannose (AP), a high mannose biological response modifier (BRM) purified from the Aloe barbadensis Miller plant, was tested for activity in enhancing antibody titres against coxsackievirus B3 (CVB3) and CVB3-induced myocarditis in murine models of the disease. Inoculation of mice with AP over a range of three nontoxic doses and in varying schedules did not reduce virus titres in heart tissues or ameliorate virus-induced cardiopathological alterations during acute disease. However, this BRM was found to significantly enhance titres of anti-CVB3 antibodies produced during acute infection of three strains of mice with CVB3. Simultaneous intraperitoneal inoculation of AP at a dose of 0.5 mg/kg body weight per mouse with purified CVB3 significantly increased ELISA titres of anti-CVB3 antibodies and the proportion of mice with these titres, compared with similar parameters in mice inoculated only with CVB3. The data conclusively show that AP can immunopotentiate antibody production against capsid protein epitopes of a nonenveloped picornavirus and suggest this BRM (AP) might be of benefit in enhancing antibody titres against other enteroviruses during a natural infection and poliovirus vaccine strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1099-1573(200006)14:4<261::aid-ptr579>3.0.co;2-a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a colloidal gold-based immunochromatographic strip for rapid detection of .
Front Microbiol
February 2025
School of Breeding and Multiplication (Sanya Institute of Breeding and Multiplication), Hainan University, Haikou, China.
Background: (APV1), the causal agent of betel palm yellow leaf disease (YLD), has caused significant yield losses and decreased product quality of betel nuts, posing a serious economic threat to local farmers. There is an urgent need for a convenient and reliable method for the rapid detection and surveillance of APV1.
Methods: The Capsid protein (CP) of APV1 was expressed in and purified as antigen to immunize BALB/c mice.
Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count.
J Korean Med Sci
March 2025
Emerging Infectious Diseases Research Institute, Chungnam National University Hospital, Daejeon, Korea.
Background: We evaluated severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)-specific humoral and cellular responses for up to 6 months after the 3rd dose of ancestral coronavirus disease 2019 (COVID-19) vaccination in people living with HIV (PLWH) and healthy controls (HCs) who were not infected with COVID-19.
Methods: Anti-spike receptor-binding domain IgG (anti-RBD IgG) concentrations using chemiluminescence immunoassay and neutralizing antibodies using focus reduction neutralization test (FRNT) were assessed at 1 week after each dose of vaccination, and 3 and 6 months after the 3rd dose in 62 PLWH and 25 HCs. T-cell responses using intracellular cytokine stain were evaluated at 1 week before, and 1 week and 6 months after the 3rd dose.
Investigation of the Blood Microbiome in Horses With Fever of Unknown Origin.
Vet Med Sci
March 2025
College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
Background: Fever of unknown origin (FUO) without a respiratory component is a frequent clinical presentation in horses. Multiple pathogens, both tick-borne and enteric, can be involved as etiologic agents. An additional potential mechanism is intestinal barrier dysfunction.
View Article and Find Full Text PDFA great deal of evidence has accumulated suggesting an important role of mucosal immunity not only in preventing COVID-19 but also in the pathogenesis of this infection. The aim of the study was to evaluate the levels of secretory immunoglobulin A (sIgA) in different compartments of the upper respiratory tract in COVID-19 patients in relation to the severity of the disease and treatment with a bacteria-based immunomodulating agent (Immunovac VP4). The titers of sIgA were determined by ELISA in nasal epithelial swabs, pharyngeal swabs, and salivary gland secretions at baseline and on days 14 and 30 of treatment.
View Article and Find Full Text PDFAcellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses.
Pediatr Infect Dis J
March 2025
National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Background: A birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters.
Methods: Children from our previous randomized controlled trial who received a monovalent 3-component aP and hepatitis B vaccine at birth (aP group) or hepatitis B only (control group) followed by Infanrix hexa at 2, 4 and 6 months of age were randomized to receive either high or low-dose diphtheria-tetanus acellular pertussis combination vaccine (DTPa-Infanrix/dTpa-Boostrix) at 18 months and 4 years of age.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!